Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, but I did save a bunch of money by switching my car insurance.
Yea and everyone is sick of them!
GM ----- man, watching a bit of TWC this morning....those
darn tropical storm formations STACKING up again ----
geez, enuf is enuf !!
Do you have a bomb shelter?
Yup, entire state is taking on shades of Detroit, Baltimore, Newark, etal.
Kansas City, MO.
St. Louis, MO.
now two of worst in country!
Follow the bouncing ball ---- it's crystal clear!
Sorry about that, maybe just a few select targets. :)
Hey now, I just looked at the map. That's a really bad idea. What's alternate plan b?
Absolutely...honestly words fail me when I want to sing the praises of all those who came together in relief...God Bless them all.
Words also fail me when I want to say something about those determined to destroy this Country.
Just Sad...
St Louis, next place to enter the air strike list. :)
Lest we forget ~~~ thx. E !
http://www.usdebtclock.org/
debt clock reached the target 20........
Added to STNG at 3.55
Would be great to get a "coffee break"!!!!!!!!!!!!!
And....down 2.6 cents....Hmmmmm
OWC Pharma Issues Chairman's Letter to Shareholders
PR NEWSWIRE 7:00 AM ET 09/14/17
Symbol Last Price Change
FOMX 5down 0 (0%)
OWCP 0.267down -0.020505 (-7.13%)
QUOTES AS OF 04:00:00 PM ET 09/14/2017
PETACH TIKVA, Israel, September 14, 2017 /PRNewswire/ --
OWC Pharma , a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders.
Letter from the Chairman,
To our Shareholders,
Following my recent appointment as Chairman at OWC Pharma , it is my pleasure to introduce myself to you and to initiate a new tradition of biannual shareholder update letters.
On the personal front, I am a biologist by training with a D. Phil. Degree from Oxford University in Cell Biology and Immunology. I have been involved in diagnostics, pharmaceutical and biotechnology (medical and agricultural) companies at CEO level since 1989 and I have run both private and public companies in this sector in Brazil, China, England, Israel and the United States. My roles in these companies have included operational and strategic elements. I currently serve as CEO of FuturaGene Ltd., an agricultural biotech company. I have been the manager of the company since its inception, leading it through a series of private fundings, a reverse merge on the AIM Exchange of the London Stock Market, a successful secondary offering in London and the ultimate sale of the company to Suzano Pulp and Paper in Brazil in a cash transaction which valued the company at US $100 million. As CEO of FuturaGene, I successfully obtained the first ever regulatory approval to commercially deploy a genetically modified commercial tree species. In addition to my role as Chairman at OWC Pharma, I also currently serve as Chairman at Foamix Pharmaceuticals(FOMX) , a specialty dermatology company, inter alia. In my early years as an Executive Director at Foamix, I was responsible for European Business Development, and in this role, I cemented an out-licensing deal with Bayer Pharmaceuticals for the development and commercialization of a topical drug for Rosacea. Marketing of this drug was initiated in late 2015 after FDA approval and today yields multi-million dollar annual royalties to Foamix. In my role as a Director and Chairman at Foamix, I have been actively involved in Foamix's IPO and two follow-on offerings on NADAQ, which in aggregate raised approximately $170 million. I believe that the experience I have acquired in these endeavors will be a strong factor in assisting in the development of OWC Pharma.
It has also been my pleasure to work closely in the past with Mr. Mordechai Bignitz, our CEO. I believe that our complementary skills and our proven ability to work successfully together will play a very positive role in helping take our company to new levels of achievement.
Research and Development
Our company is focusing on developing high level cannabis-based products for dealing with unmet medical needs in specific fields. In this respect, we have progressed in a number of areas over the last 8 months:
During this period, we completed a pre-clinical efficacy study in psoriasis with unique, and what we believe may be breakthrough results; we previously reported an up to 70% reduction in biological markers directly related to this disease;
We have received the first everInstitutional Review Board (IRB) approval to conduct a safety study for a cannabis-based topical cream with more than 3% THC and we are actively conducting a safety study (FDA Phase 1 equivalent) in one of the biggest academic hospitals in Israel. We will update the public with material developments in this area as they occur.
We filed for intellectual property (IP) protection for various delivery methods to treat different diseases, a very rare approach in the medical marijuana industry; the attainment of IP protection could represent a significant asset for our company;
We have completed the development of an orally disintegrating tablet, an important new delivery form;
Our topical cream for Psoriasis is market ready
We reported on status in our Multiple Myeloma program and we will continue to report on any material progress in that connection
Our research activities are led by Dr. Yehuda Baruch. Dr. Baruch served as Head of the Israeli Ministry of Health's Medical Marijuana Program from 2003 through 2013 where he spearheaded the efforts on regulation, chaired the indication committee, secured Helsinki Approvals for medical research, and managed regulation of patient licensing and dosage. He has extensive experience in researching medical cannabis, most notably for its effect on PTSD. Dr. Baruch is a globally acknowledged expert in the field of medical marijuana. His contributions and expertise have been and will continue to be a major factor in our development as one of the leaders in this field and provide strong scientific basis to all our endeavors. As Chairman, it has been my privilege to work with Dr. Baruch in advancing our company.
Note to our Shareholders: Further to the above report, we will, in general, provide broad guidance on our development timetables, but we will do this with due caution as the course of research and development is, by nature, uncertain - it is difficult to put a precise timeline on scientific studies. We will not provide responses to individual approaches between our public communications.
Corporate level & Business Development
Business Development :
General
Cannabis for medical purposes (also known as "medical Cannabis") is a new and infant industry with no internationally accepted standards or protocols. Many states that implemented or are about to implement Medical Cannabis bills are still to determine and pass formal sets of regulations, especially when related to products (such as our Topical cream for skin conditions), that include 3% THC or more. We are now in the process of completing a strategic analysis to determine the optimal markets and the best possible way to penetrate these markets. In this context:
We have taken proactive steps in various territories including, but not limited to appointing Mediq as our market access consultant for Germany;
We are exploring other potential markets and maintaining an ongoing dialogue with various potential business partners including representatives, manufacturers and distributors.
Corporate level
Our senior management team has been strengthened by the inclusion of two experienced professionals: Mr. Yossi Dagan, CPA (IL), as our Chief Financial Officer (CFO) and myself, as your Chairman.
We have paid down all outstanding debt and the company is now well positioned to deploy capital solely for its development needs;
We announced our initiative to cross-list our stock to the TSX and we are evaluating the possibility of cross-listing our stock on additional exchanges to increase trading liquidity as well as to facilitate our ability to raise capital to enhance our development and commercialization efforts.
As a management team, it is our vision to develop OWC Pharma as the leading cannabis-based specialty pharma company. Over the last few months we have executed on a number of important steps in order to fulfill this vision. We appreciate your continued support and interest in OWC Pharma as we move along this pathway to help patients improve their quality of life with validated and tested medication and to create value for our shareholders.
I look forward to updating you in the future,
Yours sincerely,
Dr. Stanley Hirsch,
Chairman
Notice Regarding Forward-Looking Statements
This Letter to Shareholders contains 'forward-looking statements' as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this Letter, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp.(OWCP) reports filed with the Securities and Exchange Commission.
Contact Information:
Mordechai Bignitz
Chairman and CEO
E-mail: mordechai.bignitz@owcpharma.com
Tel: +972(0)-3-770-8526
SOURCE OWC Pharmaceutical Research Corp.(OWCP)
Teekay Tankers' stock jumps 2.8% premarket after share buyback announcement
MARKETWATCH 8:33 AM ET 09/15/17
(END) Dow Jones Newswires
09-15-170833ET
Copyright (c) 2017 Dow Jones & Company, Inc.
Homemade bomb on London subway train injures at least 22, declared terrorist attack
MARKETWATCH 7:46 AM ET 09/15/17
Passenger: 'Everyone just ran off the train. It was quite scary.'
An explosion Friday on a London Underground train during the morning rush hour has left passengers with burns and has been declared a terrorist incident by British authorities.
People suffered burns as a white bucket in a bag exploded on a District Line train, according to multiple media reports.
London's Metropolitan Police said on Twitter (
) that the event at the Parsons Green station in West London has been "declared a terrorist incident," and its counter-terrorism specialists were investigating.The Met’s Counter Terrorism Command are investigating after the incident at #ParsonsGreen tube station is declared a terrorist incident
— Metropolitan Police (@metpoliceuk) September 15, 2017
) it had taken 18 patients to a number of London hospitals, with none of them "thought to be in a serious or life-threatening condition." U.K. health authorities said four other people went to hospitals on their own, bringing the tally for those injured to at least 22, according to a BBC report (http://www.bbc.co.uk/news/live/uk-england-london-41218382?ns_mchannel=social&ns_ source=twitter&ns_campaign=bbc_live&ns_linkname=59bbb83be4b0837b3c345c25%26Twenty-two%20people%20being%20treated%20in% 20hospital%26&ns_fee=0#post_59bbb83be4b0837b3c345c25).We have taken 18 patients to a number of London hospitals. None are thought to be in a serious or life-threatening condition #ParsonsGreen pic.twitter.com/3B13JznAqZ
— London Ambulance Service (@Ldn_Ambulance) September 15, 2017
)#parsonsgreen pic.twitter.com/0OUV819EtE
— Sylvain Pennec (@sylvainpennec) September 15, 2017
)We have a number of resources and specialists officers in attendance at the incident at #ParsonsGreen tube station https://t.co/GYOEv6kMua pic.twitter.com/bdiCr4hWcZ
— London Fire Brigade (@LondonFire) September 15, 2017
)PM: My thoughts are with those injured at Parsons Green and emergency services who are responding bravely to this terrorist incident.
— UK Prime Minister (@10DowningStreet) September 15, 2017
)The @metpoliceuk have confirmed that the explosion on a train at Parsons Green Station is being treated as terrorism https://t.co/4jRHedcBXt pic.twitter.com/Vbt5uCFpih
— Sadiq Khan (@SadiqKhan) September 15, 2017
)Another attack in London by a loser terrorist.These are sick and demented people who were in the sights of Scotland Yard. Must be proactive!
— Donald J. Trump (@realDonaldTrump) September 15, 2017
Sort of same down here under the bridge ----- entire
week - 10 days now in the 80's (low high 50's) ----
a little second summer going on.
I look forward to fall --- my favorite time of the year....
love the color changes (which have already started a bit here)
and the crisp morning temps. I know I'm in DOGGIE HEAVEN
when Lily and I walk and do NOT even break a sweat!
I had hoped to make it up there this summer....alas, did
not happen. I will get there ---- and, when I do ----
COFFEE break on EZ !
GL in FFB this weekend ----- GOooooooooooooo PACKERS!!
Howdy EZ....finally getting summer the past few days!!!!!! Rain now but still warm!!! White stuff better stay away for awhile as zero spring or summer til now...........
GM 906
Same down here ---- well, what I mean is northern INDIANA.
Dad used to take me to LAKE GEORGE when I was very young ---
lake is right on Indiana/Michigan border ----- LAKE actually
in both states.
We would hook into some monster perch ----- but, those days
are long gone ----- last time I fished that lake with my B-I-L,
we caught fish (the size of) that most use as BAIT !
Not walleye issues ---- but, over population, boats, jet skis
and over fished for a long time.
Got SNOW !
Hey DA....They Used to be abundant here when I was a kid,,,, the planted Walleye seemed to wipe them out though.............
brook and rainbows
What kind of trout?
Thanks. We don't have many around here.
I have the itch to catch some nice ones. Looking at scheduling an ice fishing trip with the Perch Patrol on Devil's Lake, ND, unless I can find something closer.
http://www.perchpatrol.com/
On FIT- still heavily shorted:
Short % of Float 26.76%
When I lived in New York, I was catching 14-15" in a old quarry north of Watertown. I haven't found a good spot in Wisconsin yet. Trout fishing is decent here
Looks really sweet. What I'm looking at doesn't require a passport, the fishing is world class too. Ever caught a jumbo perch?
Are you seeing a buy signal on STNG? With the tensions of the world, tankers may see some upside
FIT chart is looking pretty good. If it breaks $7ish, could really go, imo
Grins....just thought you might need a refresher...
LOL ~~~ now there is a TRUE statement ---- pic!!
For the sake of the Peach Crop in Central Texas.....lets just hope we have a serious Winter here....and some SNOW dammit....***Grins***
Stock market heads to records as investors await Apple device update
MARKETWATCH 9:40 AM ET 9/12/2017
By Mark DeCambre and Barbara Kollmeyer, MarketWatch
Monday's rally looks likely to be followed up by more gains
U.S. stock indexes on Tuesday opened higher and the S&P 500 set a fresh all-time, intraday high as a resurgence in buying on Wall Street was helped in part by optimism around Apple's expected delivery of a fresh update to its coveted gadget lineup.
Dow Jones Industrial Average rose 57 points, or 0.3%, 22,112, while S&P 500 added 5 points, or 0.2%, to 2,493, marking a new intraday day high previously at 2,490.87. The Nasdaq Composite Index , meanwhile, moved up 16 points, or 0.3%, to 6,448, trading above its recent closing high. All three benchmarks were at or near records.
Check out: MarketWatch's coverage of Delivering Alpha (http://blogs.marketwatch.com/thetell/2017/09/12/delivering- alpha-live-blog/#wysiwygEditor)
Tuesday's moves come after the S&P 500 and the Dow industrials logged their biggest one-day percentage gains (http:// www.marketwatch.com/story/dow-futures-up-more-than-100-points-as-fears-ease-over-hurricane-irma-north-korea-2017-09-11) in months. The S&P 500 finished up 1.1% to reach an all-time high of 2,488.11, while the Dow retook a key level, closing up 1.2% at 22,058.37.
At the same time, the Nasdaq climbed 1.1%. Stocks rallied after Hurricane Irma caused less damage than expected, and as tensions around North Korea eased.
Read:This legendary value-investor is another stymied by expensive stocks (http://www.marketwatch.com/story/expensive- stocks-frustrate-another-value-investing-legend-report-says-2017-09-11)
Apple Inc. (AAPL), which is holding an event later Tuesday, rose by 0.3%, after Monday's 1.8% gain. Investors expect the iPhone maker to reveal its 10th anniversary mobile phone, which reportedly has a price tag of around $1,000 (http:// www.marketwatch.com/story/new-apple-iphones-key-feature-is-its-price-tag-2017-09-09). The Cupertino, Calif.-based company's keynote presentation is slated to commence at 1 p.m. Eastern.
Also read: What time is the iPhone launch event? (http://www.marketwatch.com/story/apple-sets-date-for-event-where- new-iphone-expected-to-be-launched-2017-08-31)
Opinion:Apple's new iPhone won't move the stock the way these drivers could (http://www.marketwatch.com/story/apples- iphone8-wont-move-the-stock-the-way-these-drivers-could-2017-09-11)
(http://www.marketwatch.com/story/apples-iphone8-wont-move-the-stock-the-way-these-drivers-could-2017-09-11) (http:// www.marketwatch.com/story/apples-iphone8-wont-move-the-stock-the-way-these-drivers-could-2017-09-11)And:Tired of the FANG gang? These 2 tech stocks look like they're in the same class (http://www.marketwatch.com/story/tired-of-the-fang- gang-these-2-tech-stocks-look-like-theyre-in-the-same-class-2017-09-11)
"Today's focus will all be on technological stocks, as Apple is set to unveil its newest iPhone, entitled iPhone X, which will feature facial recognition as well many new aesthetics and new improvements to the already existing features it has," said Hassan Kanaan, senior research associate at Royal Financial/RFXT in Beirut, in a note to clients.
(http://www.marketwatch.com/story/expensive-stocks-frustrate-another-value-investing-legend-report-says-2017-09- 11)Economic data on tap for Tuesday is headlined by a reading on job openings for July, scheduled for release at 10 a.m. Eastern. Data earlier showed sentiment among small-business owners ticked up in August (http://www.marketwatch.com/ story/small-business-capital-spending-plans-jump-to-post-recession-high-2017-09-12).
Moving stocks: Shares of Teva Pharmaceuticals Industries Ltd.(TEVA) rose nearly 11% after Israeli-based pharmaceutical group said late Monday it will sell its Pargard IUD product (http://www.marketwatch.com/story/cooper-cos-buys-teva-iud- line-for-11-billion-2017-09-11) to Cooper Cos.(COO) for $1.1 billion in cash. Cooper shares were off 0.3%.
Equifax Inc.(EFX) shares rose 0.8%. Standard & Poor's announced late Monday a downgrade of its outlook on the credit- reporting agency (http://www.marketwatch.com/story/equifax-outlook-lowered-to-negative-by-standard-and-poors-2017-09-11) to negative from stable in the wake of a recent breach that put the data of 143 million Americans at risk. Equifax shares fell 8.2% on Monday.
Read:Equifax lobbied for more lax regulations ahead of massive data breach (http://www.marketwatch.com/story/equifax- lobbied-for-more-lax-regulations-ahead-of-massive-data-breach-2017-09-11)
Other markets:Asian markets (http://www.marketwatch.com/story/nikkei-hits-best-intraday-level-in-a-month-as-asian- markets-extend-gains-2017-09-11) saw tepid gains, outside of a 1.2% rally for the Nikkei which hit its best intraday level in a month as the yen continued to fall against the dollar. The dollar index , meanwhile, was modestly higher, marked by that stronger dollar/yen cross.
The British pound hit the highest level this year (http://www.marketwatch.com/story/dollar-falls-against-pound-with- sterling-at-2017-high-on-rate-hike-prospects-2017-09-12) after U.K. inflation rose by more than expected.
Read: Why the Swiss central bank may be betting on a stronger euro (http://www.marketwatch.com/story/why-the-swiss- central-bank-is-betting-on-a-stronger-euro-analysts-say-2017-09-11)
The Stoxx Europe 600 index put on about 0.5%. Oil prices drifted lower, and gold prices also fell modestly.
-Mark DeCambre; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
09-12-170940ET
Copyright (c) 2017 Dow Jones & Company, Inc.
LOL morning...she says Hi back
One day EZ...hopefully soon
If you can't join'em, may as well beat'em. lol
Top of the morning to ya, Michael. Please tell Lady Di "hello" as well.
Legal and Medical Cannabis Sales Projected to Grow as More States Adopt
FinancialBuzz.com News Commentary
PR NEWSWIRE 9:00 AM ET 9/12/2017
Symbol Last Price Change
GOHE 0.024up 0 (0%)
MJNA 0.0828up 0 (0%)
OWCP 0.305up 0 (0%)
TRTC 0.2291down 0 (0%)
QUOTES AS OF 03:47:17 PM ET 09/11/2017
NEW YORK , September 12, 2017 /PRNewswire/ --
According to a report by New Frontier Data, medical cannabis sales in 2017 are forecast to grow to $5.3 billion, which is 67% of total cannabis sales. The report projects that by 2025, medical sales in current legal states are forecast to grow to $13.2 billion, which will account for 55% of total cannabis sales. Adult use sales in 2017 are forecast to reach $2.6 billion, or rising to $10.9 billion by 2025. New Frontier also indicates that legal cannabis sales in California alone are projected to reach $2.8 billion in 2017 and $6.6 billion by 2025, with a compound annual growth rate of 12% over the next eight years. Medical cannabis products are now legal in 29 states and Washington DC. Global Payout(GOHE), Inc. (OTC: GOHE), Medical Marijuana(MJNA), Inc. (OTC: MJNA), Terra Tech Corp. (OTC: TRTC), OWC Pharmaceutical Research Corp.(OWCP) , CV Sciences, Inc. (OTC CVSI).
"Significant changes are already underway in California for medical cannabis and adult use laws, which we see will have major implications for the cannabis industry, including ecommerce and delivery services in the state," said Giadha Aguirre de Carcer, New Frontier Data CEO. "As the largest state in the country - and the largest potential market for cannabis products - the implications for the growth of the industry because of California's adult use market cannot be overstated."
Global Payout, Inc. (GOHE) (OTC: GOHE) on August 21st announced that, "its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC," the "Company") has finalized a business development agreement with Pot Saver, a Southern California-based community periodical providing listings on discounted cannabis-related products for local dispensaries and shops. Per the agreement, MTRAC will provide Pot Saver with fundamental support and guidance needed to execute its go-to-market strategy.
The Company expects that as early as Q4 2017, this agreement will enable MTRAC to generate revenue earnings from service agreements facilitated on behalf of Pot Saver, while providing both companies an opportunity to benefit from rampant market growth."
"With the medical and recreational cannabis industry growing at an unprecedented rate in California, we are determined to be conscious of the multiple opportunities that currently exist, or that we can create for MoneyTrac to further expand its brand throughout the industry as well as tap into every available revenue source possible," said MTRAC COO Vanessa Luna. "This agreement with Pot Saver is an excellent opportunity for us to offer the industry-specific business development expertise we have acquired to help further Pot Saver's go-to-market strategy, while simultaneously creating a new source of revenue for our company as we continue to expand our own brand throughout the industry."
Although the development and offering of financial technology solutions for companies and businesses in alternative and "high-risk" industries such as cannabis remains at the core of MTRAC's business focus, the Company will continue to explore additional ventures within the industry that can further its market reach and generate new avenues of revenue for Global and all its subsidiaries.
Medical Marijuana, Inc. (MJNA) (OTC: MJNA) is the first-ever publicly traded cannabis company in the United States. The company recently announced that August 2017 was the Company's largest revenue month in its history. Additionally, wholly-owned subsidiaries Kannaway® and HempMeds® Mexico experienced their largest months of revenue in their respective histories. "As we continue to expand into new markets, we are proud to watch the Company achieve milestone after milestone," said Medical Marijuana, Inc.(MJNA) CEO Dr. Stuart Titus. "Our portfolio of companies continues to create exciting developments in the cannabidiol (CBD) sector. Medical Marijuana, Inc.(MJNA) and our portfolio of companies are on track for a banner year, in terms of gross sales revenue figures."
Terra Tech Corp. (TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Recently, the company announced it has filed a patent application with the U.S. Patent and Trademark Office for innovative cannabis-infused rolling papers. The inventive rolling papers, which are expected to launch in 2018, will be the latest addition to the Company's portfolio of IVXX™ branded premium cannabis products, which includes flowers, concentrates, custom-rolled joints and edibles. As with all IVXX products, the rolling papers will be free of toxic pesticides, harmful molds and chemical residues.
OWC Pharmaceutical Research Corp. (OWCP) , through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., is conducting medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
CV Sciences, Inc. operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. The company recently announced that its industry dominating brand of finished products, PlusCBD Oil™ will be exhibiting at Natural Products Expo East on September 14-16, in Baltimore, Maryland. Produced by New Hope Network, Natural Products Expo East is the leading trade show in the natural, organic and healthy products industry held on the East Coast, attracting over 28,000 industry professionals and 1400 exhibits to the BaltimoreConvention Center.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated three thousand seven hundred fifty dollars for financial news dissemination and pr services by a non-affiliate third party for global payout, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
Pathetic is putting it mildly...the scary thing is they breed...and pass their evil hatred on to their offspring...sic...
Morning EZ...funny how as kids that's the way we were....until taught otherwise.
And, then there are these sick ba^^$&*^* who
wish harm on others ----- pathetic !!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134539688
Followers
|
226
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
120381
|
Created
|
07/13/01
|
Type
|
Premium
|
Moderators HoosierHoagie |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |